ad5-ycd/muttksr39rep-adp
Gene therapyexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2006 (NCT00415454)
Timeline
Indications
Mechanism of action
- Oncolytic virusSupplementation
Oncolytic virus supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ad5-ycd/muttksr39rep-adp
- ad5-ycd/muttksr39rep-adp adenovirus
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04739046 | Phase 2 | Feb 1, 2021 | NewGenPharm Inc., Seoul National University |
| NCT03029871 | Phase 1 | Jan 13, 2017 | Henry Ford Health System |
| NCT02894944 | Phase 1 | Aug 1, 2016 | NewGenPharm Inc., Seoul National University |
| NCT00583492 | Phase 2 | Dec 1, 2007 | Henry Ford Health System |
| NCT00415454 | Phase 1 | Nov 1, 2006 | Henry Ford Health System |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Henry Ford Health System | Academic/Hospital | 3 | 3 | 2 | 2006 |
| NewGenPharm Inc. | For profit | 2 | 0 | 2 | 2016 |
| Seoul National University | Academic/Hospital | 2 | 2 | 2 | 2016 |
3 organizations
Page 1 / 1